Professor Hiddo Heerspink
University Medical Centre Groningen, Groningen (Netherlands (The))
Q&A - Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.
Event: ESC Asia with APSC & AFC 2020
Topic: Renal Failure and Cardiovascular Disease
Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i
Challenging paradigms and changing the course of chronic kidney disease the era of SGLT2i.
Event: ESC Asia with APSC & AFC 2020
Topic: Renal Failure and Cardiovascular Disease
Session: Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i
What are the mechanisms linking novel antidiabetic treatments to cardiovascular benefit?
Event: ESC Congress 2020
Topic: Diabetes and the Heart
Session: Balancing Treatment Needs for Diabetic Patients with Cardiovascular Disease
Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial
Event: ESC Congress 2020
Topic: Antidiabetic Pharmacotherapy
Session: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy
DAPA-CKD - Dapagliflozin in Patients with Chronic Kidney Disease
Event: ESC Congress 2020
Topic: Renal Failure and Cardiovascular Disease
Session: Hot Line DAPA-CKD
Hot Line DAPA-CKD.
Event: ESC Congress 2020
Topic: Renal Failure and Cardiovascular Disease
Session: Hot Line DAPA-CKD
ESC 365 is supported by
